We would like to use third party cookies for our own marketing purposes. We do not monetise your data otherwise.
Industries
About Us
Our Work
GPU-accelerated computing for R&D modeling
Predictive maintenance cuts downtime expenses
Digital twins accelerate scale-up and process design
AI vision ensures 100% inspection zero label errors
Accelerating Innovation with Regulatory Compliance
TechnoLynx helps pharma and biotech companies boost R&D, optimise manufacturing, and ensure quality using advanced AI and high-performance computing. We solve industry challenges-like contamination prevention and faster drug discovery-while meeting strict regulations. Our solutions deliver faster market entry, higher yields, fewer failures, and stronger compliance.
TechnoLynx combines technical innovation (AI, machine learning, computer vision, GPU computing) with business impact (cost and time savings, risk reduction, productivity).
HPC and AI accelerate simulations by 10-300×, enabling faster drug discovery, quicker breakthroughs, and reduced time-to-clinic.
Machine learning maximises yield and minimises downtime, improving output and consistency. Predictive analytics enable proactive maintenance, cutting downtime and costs by ~30-40%.
Virtual simulations and digital replicas enable risk-free experimentation, reducing commissioning time and shortening development cycles by up to 90%.
AI vision systems inspect every product and package, ensuring 100% quality control, zero defects, and preventing costly recalls.
AI analytics uncover patterns in vast datasets, guiding insight-driven innovation, accelerating research, and enabling faster product development and IP creation.
The Technology Behind the Impact
Solves
Approach
Example
Transform your processes with advanced visual recognition and analysis. Our services feature expertise in classical computer vision, human-supervised system design for legal compliance, video pipeline optimisation with tools like FFmpeg, custom adaptable models, and explainable AI for ethical transparency.
We are leaders in generative and agentic AI — with optimised inference for faster deployments, bias-mitigated ethical AI, autonomous agent workflows for regulated workflows, and advanced simulation and prototyping capabilities.
We deliver immersive XR solutions with cross-platform development (Unity 6), GPU performance optimisation, and expertise in NVIDIA Omniverse and CloudXR. We also use reinforcement learning for intelligent XR environments.
TechnoLynx delivered the project on time and provided quality outputs that met the client's expectations. The team was proactive in providing ideas and suggestions, and they were careful at properly planning the tasks. The client also praised the team's expertise in GPU programming and AI.
Guido Meardi - CEO
TechnoLynx's skill in low-level software development was impressive. TechnoLynx was able to create four prototypes with common components and an interface for easy maintenance. The client was extremely happy with the solution's speed. Moreover, their communication was seamless and straightforward.
Alex Farrant - Director
TechnoLynx's unique aspect is that they're able to transform complex theories into practicable and applicable results. TechnoLynx provides research reports and architecture planning documents. The team is able to transform complex theories into practicable and applicable results. TechnoLynx's project management is strong and delivers work on time without hardware issues, being responsive through virtual meetings.
Forrest Smith - CEO & Co-Founder
I’m delighted with our collaboration with their team. Thanks to TechnoLynx's work, the client has been able to co-author two patents. They lead responsive project management to solve problems quickly. The team also praises their skilled and knowledgeable team.
Gil Hagi - CEO
We had high-efficiency meetings. TechnoLynx’s work resulted in a successful breakthrough, and their input improved the client’s app. Their flexible and organised project management cultivated a healthy collaboration experience. Ultimately, their professionalism and commitment were impressive.
Anonymous - CEO
We deliver "validation-ready" AI solutions designed for strict regulatory scrutiny. Our validation support includes:
TechnoLynx employs "Privacy by Design" to monitor processes, not people. Our systems ensure compliance without using biometric identification. All data handling is strictly aligned with GDPR and GMP data integrity standards, ensuring human supervision without compromising individual anonymity.
Yes, our models are hardware-agnostic and assay-specific. We specialize in custom model adaptation, tuning our vision algorithms to work with your specific imaging hardware, lab conditions, and proprietary assay requirements to ensure robust performance across diverse platforms.
We provide a comprehensive xAI Governance Toolkit for regulatory review. This includes:
We achieve deterministic low latency through GPU performance engineering. By leveraging asynchronous compute and multi-GPU orchestration, we provide high-throughput visual inspection that meets real-time production requirements without compromising validation controls.
Our data management follows the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, and Accurate). We provide:
Yes — waiting is the strategic error. Several AI use cases in pharma manufacturing already have proven validation pathways under CSA, CSV, GAMP 5 second edition, and Annex 11; the regulatory perimeter is often narrower than internal teams assume, and well-scoped systems can be deployed without expanding the audit surface unnecessarily — see why pharma delay costs more than adoption, CSA vs CSV for AI systems, and proven AI use cases in pharma manufacturing today.
20/04/2026
Pharma AI adoption stalls from regulatory misperception, scope inflation, and transformation assumptions. Each delay has a measurable manufacturing cost.
CSA and full CSV are different validation approaches for AI in pharma. The right choice depends on system risk, not regulatory habit.
24/04/2026
GAMP 5 categories were designed for deterministic software. AI/ML systems require the Second Edition's risk-based approach and continuous validation.
15/05/2025
See how TechnoLynx helped CloudRF speed up signal propagation and tower placement simulations with GPU acceleration, custom algorithms, and cross-platform support. Faster, smarter radio frequency planning made simple.
10/12/2024
Hierarchical SKU classification using DINO embeddings and few-shot learning — above 95% accuracy at ~1k classes, above 83% at ~2k.
20/11/2024
Browser-deployed face quality classifier rebuilt around a single multiclassifier, WebGL pixel capture, and explicit device-capability gating.
20/09/2024
Per-shelf share-of-shelf measurement in area and count modes, with unknown-product handling treated as a first-class operational output.
15/07/2024
In-cart perception for autonomous retail checkout: detection, tracking, adaptive FPS sampling, and a session-scoped cart-state model.
12/03/2024
See how our team applied a case study approach to build a real-time Kazakh text-to-speech solution using ONNX, deep learning, and different optimisation methods.
15/12/2023
Case study on moving a GPU application from OpenCL to Metal for our client V-Nova. Boosts performance, adds support for real-time apps, VR, and machine learning on Apple M1/M2 chips.
15/10/2023
Camera-based barcode pipeline for in-cart capture: YOLO localisation, ensemble decoding, multi-frame polling — 86.7% vs Dynamsoft 80%.
6/06/2023
Case study on using Generative AI for stock market prediction. Combines sentiment analysis, natural language processing, and large language models to identify trading opportunities in real time.
15/05/2023
How TechnoLynx modelled AI inference performance across GPU architectures — delivering two tools (topology-level performance predictor and OpenCL GPU characteriser) plus engineering education that changed how the client's team thinks about GPU cost.
10/02/2023
How TechnoLynx built a cost-efficient multi-target multi-camera tracking system for a smart retail deployment — real-time tracking across non-overlapping CCTV cameras using probabilistic trajectory prediction and consistent global identity.
11/01/2023
How TechnoLynx built a hybrid action recognition system for a smart retail environment — detecting suspicious behaviour in real time using transfer learning and a rules-based approach on cost-effective CCTV.
9/05/2026
Pharma automation partners must understand GxP validation, process control, and regulatory requirements — not just industrial automation technology.
Medicine manufacturing converts APIs into dosage forms through formulation, processing, and quality control — all under cGMP regulatory oversight.
GxP validation is documented evidence that a system performs as intended. For AI software, it requires risk-based, continuous approaches.
A GxP system is any computerised system that affects pharma product quality, safety, or data integrity. Classification determines validation obligations.
GxP compliance requires validated systems, audit trails, data integrity, and change control — scoped to quality-affecting processes, not every system.
GAMP software refers to any computerised system validated under the GAMP 5 framework. The Second Edition extends coverage to AI, cloud, and agile.
8/05/2026
GAMP classifies software as Category 1, 3, 4, or 5 based on complexity and configurability. AI/ML systems challenge traditional category boundaries.
The GAMP guide provides a risk-based framework for validating automated systems in pharma. The Second Edition extends guidance to AI, agile, and cloud.
GAMP categories 1, 3, 4, and 5 determine validation effort for pharmaceutical software. Classification depends on configurability, not just complexity.
GAMP 5 provides a risk-based framework for validating pharmaceutical software. The Second Edition extends this to AI and machine learning systems.
7/05/2026
EU GMP Annex 11 governs computerised systems in pharma manufacturing. Its data integrity, validation, and access control requirements are specific.
Drug manufacturing transforms APIs into finished products through formulation, processing, and packaging. AI improves process control, inspection, and.
Continuous pharma manufacturing replaces batch processing with real-time flow. AI-based process control is essential for maintaining quality in continuous.
Computer system validation in pharma requires documented evidence of fitness for use. CSA now offers a risk-based alternative to full CSV for lower-risk.
6/05/2026
cGMP is the FDA's evolving standard for manufacturing quality. GMP is the broader WHO/EU framework. The 'current' modifier changes what compliance means.
cGMP pharmaceutical regulations define minimum quality standards for drug manufacturing. Compliance requires documentation, process control, and personnel.
Automated visual inspection in pharma uses computer vision to detect defects in vials, syringes, and tablets — faster and more consistently than human.
Aseptic manufacturing prevents microbial contamination during sterile drug production. AI monitoring addresses the environmental control gaps humans miss.
5/05/2026
CV in pharmacy retail addresses unique challenges: regulated product tracking, controlled substance security, and planogram compliance across thousands of SKUs.
AI shifts pharma compliance from periodic manual audits to continuous automated validation — catching deviations in hours instead of months.
New AI-driven monitoring systems detect contamination risk in aseptic filling by analysing environmental and process data continuously rather than via batch sampling.
Pharma supply chain AI delivers measurable ROI in three areas: serialisation verification, cold-chain anomaly prediction, and visual inspection automation.
GxP is a family of regulations — GMP, GLP, GCP, GDP — each applying different validation requirements to AI systems depending on lifecycle role.
2/05/2026
A pharma AI POC that survives GxP validation: five instrumentation choices made at week one, removing the 6–9 month re-derivation at validation handover.
25/04/2026
Annex 11 governs computerised systems in EU pharma manufacturing. Its data integrity requirements and AI implications are more specific than teams assume.
23/04/2026
CV-based pharma QC inspection is a production engineering problem, not a model accuracy problem. It requires data, validation, and pipeline design.
22/04/2026
Pharma manufacturing AI is deployable now — process control, visual inspection, deviation triage. The approach is assessment-first, not technology-first.
21/04/2026
GxP applies to AI software that affects product quality, safety, or data integrity — not to every system in a pharma facility. The boundary matters.
Pharmaceutical batch failures cost waste, rework, and regulatory exposure. AI-based process control prevents the failure classes behind most rejections.
7/01/2026
GPU computing in drug discovery: how parallel workloads accelerate molecular simulation, docking calculations, and deep learning models for compound property prediction.
6/01/2026
Where GPUs are essential in healthcare AI: medical image processing, genomic workloads, and real-time inference that CPU-only architectures cannot sustain at production scale.
16/12/2025
AI in biotech research: how machine learning accelerates compound screening, genomic analysis, and experimental design decisions in biological research pipelines.
15/12/2025
Machine learning in pharma: applying biomarker analysis, adverse event prediction, and data pipelines to regulated pharmaceutical research and development workflows.
12/12/2025
AI for rare disease diagnosis: how small dataset constraints shape model selection, transfer learning strategies, and the clinical validation requirements.
7/11/2025
Neural network visualisation: how activation maps, layer inspection, and feature attribution reveal what a model has learned and where it will fail.
9/12/2024
Hospital staff tracking system, Part 2: training the computer vision model, containerising for deployment, setting inference latency targets, and configuring production monitoring.
2/12/2024
Building a hospital staff tracking system with computer vision, Part 1: sensor setup, data collection pipeline, and the MLOps environment for training and iteration.
28/06/2024
Artificial intelligence is without a doubt a big deal when included in our arsenal in many branches and fields of life sciences, such as neurology, psychology, and diagnostics and screening. In this article, we will see how AI can also be beneficial in the field of pharmaceutics for both pharmacists and consumers. If you want to find out more, keep reading!
3/05/2024
Computer vision in medical imaging: how AI systems accelerate screening and diagnostic workflows while managing the false-positive rates that determine clinical acceptance.
